Lantheus (LNTH) Scheduled to Post Quarterly Earnings on Thursday

Lantheus (NASDAQ:LNTH) will post its quarterly earnings results before the market opens on Thursday, May 2nd. Analysts expect Lantheus to post earnings of $1.34 per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. The business had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. On average, analysts expect Lantheus to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Lantheus Stock Up 2.6 %

Shares of NASDAQ LNTH opened at $67.26 on Tuesday. The company has a 50 day simple moving average of $61.82 and a 200-day simple moving average of $62.66. The company has a market capitalization of $4.61 billion, a P/E ratio of 14.50 and a beta of 0.54. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.80 and a quick ratio of 5.45. Lantheus has a 1 year low of $50.20 and a 1 year high of $100.85.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was acquired at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. Insiders sold 94,545 shares of company stock valued at $6,169,936 in the last 90 days. Company insiders own 2.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. JMP Securities restated a “market outperform” rating and set a $100.00 price target on shares of Lantheus in a report on Friday, February 23rd. StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. B. Riley increased their price objective on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Finally, Truist Financial reaffirmed a “buy” rating and set a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and an average price target of $104.71.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.